Impact of Tafamidis on Transthyretin Concentration and Its Relation to All-Cause Mortality in Patients with Transthyretin Amyloid Cardiomyopathy: An Analysis from ATTR-ACT
6 affiliations
- 1Division of Cardiology, Cardiac Amyloidosis Program, Columbia University Irving Medical Center, Vagelos College of Physicians and Surgeons
- 2University College London
- 3Department of Chemistry, The Scripps Research Institute
- 4Cleveland Clinic
- 5Pfizer Inc
- 6Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV
Abstract
Introduction Tafamidis is approved to treat transthyretin amyloid cardiomyopathy (ATTR-CM) on the basis of results of the phase 3 study ATTR-ACT. This post hoc analysis from ATTR-ACT evaluated the effect of tafamidis on transthyretin (TTR) concentration and explored the potential relationship between changes in TTR concentration at month 1 (early ΔTTR) and all-cause mortality (ACM). Methods Patients with ATTR-CM treated with tafamidis 80 mg or placebo in ATTR-ACT who survived until month 1 were included. The independent association between early ΔTTR and ACM at month 30 was evaluated using univariate analyses, including a logistic model for ACM incidence and a Cox model for time to ACM. Baseline variables significantly influencing this relationship were identified using backward selection and included as covariates (baseline TTR concentration and National Amyloidosis Centre stage) in a multivariable Cox model. Results Tafamidis 80 mg produced a 36.3% mean increase in TTR concentration by month 1 (mean [SD] change 7.3 [3.9] mg/dL) that was sustained through month 30, whereas placebo showed minimal change at month 1 (mean change [SD] − 0.02 [2.9] mg/dL) and throughout the study period. Logistic regression showed early ΔTTR was associated with reduced odds of ACM by month 30 only in patients treated with tafamidis; every 5 mg/dL increase correlated with a 45.0% reduction in odds of ACM (p = 0.0193). In univariate analysis, every 1 mg/dL increase in TTR concentration at month 1 in patients treated with tafamidis was associated with a 9.3% hazard reduction in ACM (hazard ratio 0.907; 95% CI 0.837–0.983, p = 0.0174). Multivariable analysis showed an 8.7% reduction in hazard of ACM for each 1 mg/dL increase. Conclusions Tafamidis was associated with an early increase in TTR concentration that was sustained through month 30, and early increases correlated with reduced ACM. However, mechanisms underlying TTR concentration increases and their clinical significance remain unclear. Graphical abstract available for this article. Trial Registration ClinicalTrials.gov identifier NCT01994889. Graphical Abstract
Related
- Cardiovascular-Related Mortality and Hospitalizations in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis: A Post Hoc Analysis of the Phase 3 ATTR-ACT and Long-Term Extension
- Stage-Specific Cost-Effectiveness of Early vs. Delayed Tafamidis for Transthyretin Amyloid Cardiomyopathy in Japan
- When Earlier Is Better But Still Not Cost-Effective ― Reframing the Value of Tafamidis in Transthyretin Amyloid Cardiomyopathy ―
- Survival in a Contemporary, Real-World, Matched Cohort of Patients with Transthyretin Amyloid Cardiomyopathy Treated vs Not Treated with Tafamidis
- Sex Differences in a Contemporary, Real-World Cohort of Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis
BibTeX
@article{maurer2026impact,
title = {{Impact of Tafamidis on Transthyretin Concentration and Its Relation to All-Cause Mortality in Patients with Transthyretin Amyloid Cardiomyopathy: An Analysis from ATTR-ACT}},
author = {Mathew S. Maurer and Perry Elliott and Jeffery W. Kelly and Mazen Hanna and Evan T. Powers and Steve Riley and Rong Wang and Pablo Garcia-Pavia},
journal = {Cardiology and Therapy},
year = {2026},
month = aug,
doi = {10.1007/s40119-026-00468-2},
url = {https://doi.org/10.1007/s40119-026-00468-2},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Impact of Tafamidis on Transthyretin Concentration and Its Relation to All-Cause Mortality in Patients with Transthyretin Amyloid Cardiomyopathy: An Analysis from ATTR-ACT
AU - Mathew S. Maurer
AU - Perry Elliott
AU - Jeffery W. Kelly
AU - Mazen Hanna
AU - Evan T. Powers
AU - Steve Riley
AU - Rong Wang
AU - Pablo Garcia-Pavia
PY - 2026
DA - 2026/08/01
JO - Cardiology and Therapy
DO - 10.1007/s40119-026-00468-2
UR - https://doi.org/10.1007/s40119-026-00468-2
AB - Introduction Tafamidis is approved to treat transthyretin amyloid cardiomyopathy (ATTR-CM) on the basis of results of the phase 3 study ATTR-ACT. This post hoc analysis from ATTR-ACT evaluated the effect of tafamidis on transthyretin (TTR) concentration and explored the potential relationship between changes in TTR concentration at month 1 (early ΔTTR) and all-cause mortality (ACM). Methods Patients with ATTR-CM treated with tafamidis 80 mg or placebo in ATTR-ACT who survived until month 1 were included. The independent association between early ΔTTR and ACM at month 30 was evaluated using univariate analyses, including a logistic model for ACM incidence and a Cox model for time to ACM. Baseline variables significantly influencing this relationship were identified using backward selection and included as covariates (baseline TTR concentration and National Amyloidosis Centre stage) in a multivariable Cox model. Results Tafamidis 80 mg produced a 36.3% mean increase in TTR concentration by month 1 (mean [SD] change 7.3 [3.9] mg/dL) that was sustained through month 30, whereas placebo showed minimal change at month 1 (mean change [SD] − 0.02 [2.9] mg/dL) and throughout the study period. Logistic regression showed early ΔTTR was associated with reduced odds of ACM by month 30 only in patients treated with tafamidis; every 5 mg/dL increase correlated with a 45.0% reduction in odds of ACM (p = 0.0193). In univariate analysis, every 1 mg/dL increase in TTR concentration at month 1 in patients treated with tafamidis was associated with a 9.3% hazard reduction in ACM (hazard ratio 0.907; 95% CI 0.837–0.983, p = 0.0174). Multivariable analysis showed an 8.7% reduction in hazard of ACM for each 1 mg/dL increase. Conclusions Tafamidis was associated with an early increase in TTR concentration that was sustained through month 30, and early increases correlated with reduced ACM. However, mechanisms underlying TTR concentration increases and their clinical significance remain unclear. Graphical abstract available for this article. Trial Registration ClinicalTrials.gov identifier NCT01994889. Graphical Abstract
SN - 2193-8261
SN - 2193-6544
ER -